RT Journal Article SR Electronic T1 Progression-free Survival Is Accurately Predicted in Patients Treated with Chemotherapy for Epithelial Ovarian Cancer by the Histoculture Drug Response Assay in a Prospective Correlative Clinical Trial at a Single Institution JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1029 OP 1034 VO 33 IS 3 A1 PHILL-SEUNG JUNG A1 DAE-YEON KIM A1 MOON-BO KIM A1 SHIN-WHA LEE A1 JONG-HYEOK KIM A1 YONG-MAN KIM A1 YOUNG-TAK KIM A1 ROBERT M. HOFFMAN A1 JOO-HYUN NAM YR 2013 UL http://ar.iiarjournals.org/content/33/3/1029.abstract AB This study aimed to prospectively correlate clinical outcomes of advanced epithelial ovarian cancer (AEOC), with the results of in vitro chemosensitivity testing of taxol and carboplatin using the in vitro histoculture drug response assay (HDRA). A total of 104 patients with AEOC were treated with combination chemotherapy of taxol and carboplatin after primary cytoreductive surgery between 2007 and 2012 at the Asan Medical Center, Seoul, Korea. To compare chemosensitivity in the HDRA with clinical response, all patients were first categorized into two groups as either sensitive to both taxol and carboplatin (SS), or not sensitive to one or both drugs (R) based on HDRA results. The recurrence rate was much lower in the SS group compared to the R group; 29.2% vs 69.8%, respectively (p=0.02). The SS group had a significantly longer progression-free survival compared to the R group, 34.0 months vs 16.0 months, respectively (p=0.025). These results demonstrate that the HDRA prospectively correlates to clinical outcome from chemotherapy and that treatment regimens can be individualized based on the HDRA.